Biotech Stock Soars on AstraZeneca Buyout
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting
AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail i...
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharma in $2.4bln deal
AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126% premium to Nasdaq-listed Fusio...
AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.
AstraZeneca to cap US out-of-pocket costs for inhalers to $35
AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.
AstraZeneca Amolyt Pharma takeover ‘sufficiently modest' - analysts
AstraZeneca PLC (LSE:AZN)'s £780 million takeover of France-based Amolyt Pharma on Thursday failed to tempt much of a reaction from Deutsche Bank analysts. According to the bank, the acquisition “i...
AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline
AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
AstraZeneca to buy France's Amolyt Pharma for £780m
AstraZeneca PLC (LSE:AZN) has agreed to buy France-based Amolyt Pharma for $1.05 billion (£780 million) to strengthen the late-stage drug pipeline of its Alexion rare disease arm. Lyon-based Amolyt...
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare diseases portfolio
Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
5 Reasons AstraZeneca Stock Can Rise In 2024
AstraZeneca PLC has seen a modest 3% price rise in the past year, but there are positive factors that could drive price upside in 2024. The company has improved revenue guidance for 2024, after gui...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $66.19, moving +1.41% from the previous trading session.
Related Companies